Kennedy 1990.

Study characteristics
Methods	Trial design: Randomised controlled trial
Participants	Participants: 82 women were randomised and analysed. Mean age: Nafarelin group was 31.5 ± 5.20 years (range = 21 to 41 years), danazol group 30.2 ± 4.89 years (range = 21 to 42 years). Inclusion criteria: Pelvic pain, dyspareunia, dysmenorrhoea or infertility 24‐36‐day menstrual cycle over the preceding 4 months No hormonal treatment in the preceding 6 months, barrier comtraception throughout study Exclusion criteria: not stated Setting: United Kingdom Timing: not stated
Interventions	Nafarelin 200 μg twice daily IN with placebo tablets (n = 55) versus Danazol 200 mg three times daily orally  with placebo nasal spray (n = 27)
Outcomes	Relief of overall pain: pelvic pain, dyspareunia, dysmenorrhoea Adverse effects Improvement of most troublesome symptom Serum oestradiol levels AFS score
Notes	Intention‐to‐treat analysis: not stated Sample size calculation: not stated Funding: Supported by Syntex (U.K.) Ltd., Maidenhead, United Kingdom Author could not be contacted due to lack of information.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomly allocated, stratification on a 2:1 ratio, according to disease severity. No further details of method used to generate the randomisation sequence were provided.
Allocation concealment (selection bias)	Unclear risk	No details of method used to conceal allocation were provided.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Placebo‐controlled study
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Placebo‐controlled study
Incomplete outcome data (attrition bias) All outcomes	Low risk	Eight patients did not complete treatment and their scores were omitted; their stages at first laparoscopy were I = 2, II = 4, III = 1, and IV = 1. Four patients withdrew from the nafarelin group because of depression, muscle aches, mastalgia and bloating (1); giddiness, nausea, and vague paraesthesia on the right side of the face and left hand (1); travel abroad (1); and a maculopapular rash (1). Two patients withdrew from the danazol group because of a viral illness (1) and a maculopapular rash (1). One patient from each group was withdrawn from the study because of poor compliance.
Selective reporting (reporting bias)	Low risk	The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were prespecified.
Other bias	Low risk	No other risk of bias detected